DOCSLIB.ORG

Side Effects Revealed: Women’S Experiences with Aromatase Inhibitors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Side Effects Revealed: Women’S Experiences with Aromatase Inhibitors Side Effects Revealed: Women’s Experiences With Aromatase Inhibitors A Report From Breast Cancer Action JANUARY 2007 Side Effects Revealed: Women’s Experiences With Aromatase Inhibitors By Marilyn T. Zivian, Ph.D., and Brenda Salgado, M.S. JANUARY 2007 A Report From 55 New Montgomery Street, Suite 323 San Francisco, CA 94105 Phone: (415) 243-9301 Toll-free: (877) 2STOPBC www.bcaction.org [email protected] Th is report is dedicated to the hundreds of women who generously took the time to respond to Breast Cancer Action’s Aromatase Inhibitor Side Eff ects Survey and to everyone who seeks to make informed decisions about the care they receive. Table of Contents Executive Summary . 1 Introduction . 3 Methods . 4 Results . 5 Conclusions . 13 Acknowledgements BCA Reviewers Survey Design Assistance Barbara Brenner Diane Tompkins, Th e Curious Company Executive Director Rebecca Farmer Graphic Design Communications Offi cer Yvonne Day, Y. Day Designs Katrina Kahl Communications Associate Printing Inkworks Press Lisa Wanzor Associate Director Breast Cancer Action wishes to thank the many women who participated in the survey and the organizations and individuals who assisted in its distribution. Th is publication and quotes from survey respondents are available online at www.bcaction.org. ©2007 Breast Cancer Action Breast Cancer Action 1 Executive Summary Aromatase inhibitors (AIs) are hormonal therapies approved for use in postmenopausal women with breast cancer. Th ree AIs have been approved by the U.S. Food and Drug Administration (FDA): anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara). Because AIs are relatively new drugs, little information is available about their long-term side eff ects. Breast Cancer Action (BCA) is conducting a survey on the side eff ects women are experiencing while taking these drugs. Th e goal of this survey is to provide information about side eff ects to patients, doctors, the FDA, the National Cancer Institute, and other cancer organizations. About the Survey Th e AI Side Eff ects Survey was developed in 2005, and includes questions about the respondent’s age, place of residence, the AI prescribed, date started and date stopped (if applicable), purpose of prescription, whether the patient was given information by her health care provider about side eff ects and recommended duration of use, menopausal status at the time of prescription, and other treatments received for breast cancer. Th e questions are followed by a list of 38 side eff ects that was generated from FDA product information documents for the three AIs. Respondents rated the side eff ects for severity (none, mild, moderate, or severe). Finally, respondents were asked to report any additional side eff ects. Th e sample of respondents is self-selected and may not be representative of the population of women taking AIs. Th erefore, the results cannot be generalized to the larger population. Summary of Findings Th e fi rst 612 completed surveys received were analyzed for this report. Major fi ndings include: 1. Most respondents (96%) reported one or more side eff ects. 2. Th e side eff ects reported by over 50% of respondents were: hot fl ashes (65%), bone pain (64%), feeling tired (59%), muscle pain (58%), and insomnia (51%). 3. Many women reported side eff ects in addition to those on our list, including joint-related side eff ects, vaginal atrophy and dryness, a rise in cholesterol levels, and general pain. 4. Over 50% of respondents stated that their menopause was not naturally occurring. For these women, menopause was either pharmaceutically or surgically induced. 5. Ten women (1.6%) reported that they discontinued using an AI because of subsequent menstruation or vaginal bleeding. 6. About 30% of the respondents discontinued the use of an AI—84% because of side eff ects they were experiencing, and close to half of them (47%) specifi cally because of joint-related side eff ects. 7. Over one-third (37%) of respondents reported receiving no information from their doctors about short-term side eff ects; nearly two-thirds (63%) reported receiving no information from their doctors about long-term side eff ects. 2 Side Effects Revealed: Women’s Experiences With Aromatase Inhibitors Conclusions While the population of survey respondents is not necessarily representative of all women taking AIs, the initial results of our survey show that most women in our sample experienced one or more side eff ects. Many patients reported not receiving information from their doctors about the side eff ects of AIs. However, these are relatively new drugs and clinical trials rarely report on long-term side eff ects. Th us little information is available to doctors and patients about the long-term side eff ects of AIs. Aromatase inhibitors are indicated for use only in postmenopausal women with breast cancer. Based on responses, it is apparent that some women who are not postmenopausal are being prescribed AIs—either because they were thought to be postmenopausal but later resumed menstruating, or because they were premenopausal and had their ovarian function supressed.1 Th e survey results clearly suggest that patients need better information about the side eff ects of AIs and whether the use of AIs is actually appropriate for them. Recommendations 1. Conduct additional research on short-term and long-term side eff ects of AIs. 2. Provide the results of this research to doctors and patients. 3. Use caution when prescribing AIs to perimenopausal women, as well as to premenopausal women who have been rendered menopausal by chemotherapy or ovarian function suppression. 1 Th ree Phase III trials (SOFT IBCSG-24-02; TEXT IBCSG-25-02; PERCHE IBCSG-26-02) are currently looking at the use of exemestane in premenopausal women whose ovarian function has been suppressed either surgically, pharmaceutically, or through radiation of the ovaries. Th ese trials were started in 2003, and results will not be available for several years. Until these trials are completed, no data exist to support the use of AIs in women whose menopause is artifi cially induced. Breast Cancer Action 3 INTRODUCTION ntil recently, tamoxifen has been one of the primary drugs used in the treatment of breast cancer. When Uit was approved for use, little was known about its long-term side eff ects. Aft er being contacted by women reporting side eff ects they were experiencing, BCA published a series of articles on tamoxifen in its newsletter. As a result, BCA became an informal repository for women’s reports of side eff ects. Eventually breast cancer patients’ informal reports to doctors and others prompted side eff ects research that confi rmed their anecdotal experiences. Now, more than ten years later, AIs are quickly replacing tamoxifen as the drug of choice for treating hormone- responsive breast cancer in postmenopausal women. As with tamoxifen a decade ago, little is known about the long- term side eff ects of these drugs. Th is time, BCA decided to systematically collect data on the side eff ects women have been experiencing. BCA’s goals in providing this information are to enable patients to make better decisions, doctors to make more informed recommendations, and the FDA to monitor AI side eff ects. About Aromatase Inhibitors Aromatase inhibitors are a type of hormone therapy for postmenopausal women with breast cancer. AIs prevent the aromatase enzyme from converting the hormone androgen into estrogen. Produced by the adrenal gland and found throughout the body, androgen is the principal source of estrogen for postmenopausal women. AIs have only been approved for use by postmenopausal women. Th ey are ineff ective in premenopausal women whose ovaries are still producing estrogen (which is not aff ected by the aromatase enzyme). None of these drugs has been approved by the FDA for use by healthy women at high risk of developing breast cancer. Th ree AIs are currently approved by the FDA for the treatment of breast cancer in postmenopausal women: anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara). Anastrozole and letrozole are both nonsteroidal aromatase inhibitors. Th ey are described as reversible because they bind reversibly to the aromatase enzyme. Exemestane is a steroidal inhibitor that forms an irreversible bond with the aromatase enzyme, permanently stopping the activity of the enzyme. Th ese drugs were fi rst approved for treatment of advanced breast cancer in postmenopausal women on the following dates: anastrozole in December 1995, letrozole in July 1997, and exemestane in October 1999. Th e FDA Indication and Usage for the three AIs is as follows: 1 Anastrozole (Arimidex) • Arimidex is indicated for adjuvant treatment of postmenopausal women with hormone-receptor-positive early breast cancer. • Arimidex is indicated for the fi rst-line treatment of postmenopausal women with hormone-receptor-positive or hormone-receptor-unknown locally advanced or metastatic breast cancer. • Arimidex is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. 1 Th e indication and usage information for anastrozole, exemestane, and letrozole on pages 3 and 4 were taken from the FDA web site, www.fda.gov, in October 2006. 4 Side Effects Revealed: Women’s Experiences With Aromatase Inhibitors Exemestane (Aromasin) • Aromasin is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor-positive early breast cancer who have received two to three years of tamoxifen and are switched to Aromasin for completion of a total of fi ve consecutive years of adjuvant hormonal therapy. • Aromasin is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy. Letrozole (Femara) • Femara is indicated for the adjuvant treatment of postmenopausal women with hormone-receptor-positive early breast cancer. • Femara is indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women who have received fi ve years of adjuvant tamoxifen therapy.
Load more

Recommended publications
  • X FACT SHEET
    Letrozole For the Patient: Letrozole Other names: FEMARA • Letrozole (LET-roe-zole) is a drug that is used to treat breast cancer. It only works in women who are post-menopausal and producing estrogen outside the ovaries. Many cancers are hormone sensitive (estrogen or progesterone receptor positive) and their growth can be affected by lowering estrogen levels in the body. Letrozole is used to help reduce the amount of estrogen produced by your body and decrease the growth of hormone sensitive tumors. Letrozole is a tablet that you take by mouth. The tablet may contain lactose. • It is important to take letrozole exactly as directed by your doctor. Make sure you understand the directions. • Letrozole may be taken with food or on an empty stomach. • If you miss a dose of letrozole, take it as soon as you can if it is within 12 hours of the missed dose. If it is over 12 hours since your missed dose, skip the missed dose and go back to your usual dosing times. • Other drugs such as tamoxifen (NOLVADEX) and raloxifen (EVISTA) may interact with letrozole. Because letrozole works by reducing the amount of estrogen produced by your body, it is recommended that you avoid taking estrogen replacement therapy such as conjugated estrogens (PREMARIN, C.E.S., ESTRACE, ESTRACOMB, ESTRADERM, ESTRING). Tell your doctor if you are taking this or any other drugs as you may need extra blood tests or your dose may need to be changed. Check with your doctor or pharmacist before you start taking any new drugs. • The drinking of alcohol (in small amounts) does not appear to affect the safety or usefulness of letrozole.
    [Show full text]
  • Aromatase Inhibitors
    FACTS FOR LIFE Aromatase Inhibitors What are aromatase inhibitors? Aromatase Inhibitors vs. Tamoxifen Aromatase inhibitors (AIs) are a type of hormone therapy used to treat some breast cancers. They AIs and tamoxifen are both hormone therapies, are taken in pill form and can be started after but they act in different ways: surgery or radiation therapy. They are only given • AIs lower the amount of estrogen in the body to postmenopausal women who have a hormone by stopping certain hormones from turning receptor-positive tumor, a tumor that needs estrogen into estrogen. If estrogen levels are low to grow. enough, the tumor cannot grow. AIs are used to stop certain hormones from turning • Tamoxifen blocks estrogen receptors on breast into estrogen. In doing so, these drugs lower the cancer cells. Estrogen is still present in normal amount of estrogen in the body. levels, but the breast cancer cells cannot get enough of it to grow. Generic/Brand names of AI’s As part of their treatment plan, some post- Generic name Brand name menopausal women will use AIs alone. Others anastrozole Arimidex will use tamoxifen for 1-5 years and then begin exemestane Aromasin using AIs. letrozole Femara Who can use aromatase inhibitors? Postmenopausal women with early stage and metastatic breast cancer are often treated with AIs. After menopause, the ovaries produce only a small amount of estrogen. AIs stop the body from making estrogen, and as a result hormone receptor-positive tumors do not get fed by estrogen and die. AIs are not given to premenopausal women because their ovaries still produce estrogen.
    [Show full text]
  • Acupuncture Plus Herbal Medicine PCOS Finding
    Acupuncture Plus Herbal Medicine PCOS Finding Published by HealthCMI on 18 February 2018. Acupuncture plus herbal medicine increase the clinical effective rate of drug therapy for the treatment of polycystic ovary syndrome (PCOS). In research conducted at the Hubei Maternal and Child Care Service Center, drug therapy using cyproterone acetate/ethinylestradiol and letrozole produced an 72.5% total effective rate. Using both drugs and herbal medicine produced an 85.0% total effective rate, and the rate increased to 95.0% when acupuncture was added to the treatment regimen. Cyproterone acetate/ethinylestradiol is a commonly used medicine for the treatment of PCOS. Letrozole is an aromatase inhibitor used to stimulate ovulation in women with PCOS. The following parameters were used to evaluate treatment efficacy: menstruation improvements, body weight, body mass index (BMI), luteal hormone (LH), follicle stimulating hormone (FSH), LH/FSH ratio, total testosterone (T), and estradiol (E2)]. An enzyme linked immunosorbent assay was adopted to determine the content of anti-Mullerian hormone (AMH) and inhibin B (IHNB). In Traditional Chinese Medicine, PCOS falls under the Yue Jing Hou Qi (delayed menstruation), Bi Jing (amenorrhea), or the Bu Yun (infertility) class of disorders. Kidney deficiency is one primary cause. Binding of qi, phlegm, and stasis is a secondary cause. The treatment principle is to supplement the kidney essence, boost the liver and spleen, promote blood circulation, and dispel phlegm. Let’s take a look at the treatment protocols that achieved clinical success in the study. A total of 120 patients from Hubei Maternal and Child Care Service Center participated in the study.
    [Show full text]
  • Letrozole (Femara)
    Letrozole (Femara) Letrozole (Femara) is a medication that was first reported to be effective for ovulation induction in 2000. It is classified as an Aromatase Inhibitor (AI) and was developed to reduce the risk of recurrence of breast cancer. Even though its use is considered “off label” for fertility treatment, there is good evidence supporting its efficacy and safety for ovulation induction. How does it work? Letrozole works by binding to aromatase, an enzyme needed to make Estrogen. By temporarily decreasing Estrogen levels at the beginning of a menstrual cycle, Letrozole signals the pituitary gland to release more Follicle Stimulating Hormone (FSH). FSH stimulates the development of ovarian follicles, the fluid filled structure in which eggs reside and mature. Letrozole may lead to one or more eggs being ovulated and regulate the menstrual cycle. Ovulation typically occurs 5-8 days after the last letrozole tablet. When a mature follicle is present, a surge of LH hormone is released by the pituitary which causes the egg to be released from the follicle. Ovulation will occur 24-48 hours after the surge. What is the standard dose? The Letrozole dosage is 2.5mg for five consecutive days – typically cycle Day 3 to 7 (with cycle day 1 being the first day of full menstrual flow). It is taken orally at approximately the same time each day. How do I know when I am going to get an LH surge? The easiest way to detect your LH surge is with an ovulation predictor kit (OPK). This is a urine test that is done daily beginning a couple of days before you expect to ovulate.
    [Show full text]
  • Letrozole Use for Fertility Has Been Widely Studied
    (802)655-8888 nrmvt.com Letrozole Letrozole is an aromatase inhibitor used to induce ovulation in patients with irregular menses or no menses at all. Letrozole works to induce ovulation by blocking estrogen production, leading to increases in follicle-stimulating hormone (FSH) release. You may be prescribed this medication if you have polycystic ovary syndrome (PCOS) or problems with ovulation. The use of letrozole for ovulation induction is off-label, meaning the FDA has not approved this indication. However, letrozole use for fertility has been widely studied. Most recently, the National Institutes of Health evaluated the effect of letrozole in patients with ovulatory infertility or PCOS. Dr Peter Casson was one of the principal investigators of this national, multi-center, randomized-controlled trial published in the New England Journal of Medicine that analyzed letrozole head to head with another commonly used medication, clomiphene citrate, and found letrozole to be superior. Who may be a candidate for letrozole? 1. Patients with PCOS or ovulatory infertility. 2. Patients with other types of infertility that have side effects or contraindications to Clomid. What is the success rate? Success rates differ by female age and fertility diagnosis. In general, successful ovulation occurs in 60% of cycles, and live birth rate for patients with PCOS who are <35 years old is 15-17% per cycle. What about twins? Triplets? The risk of twins with letrozole is estimated to be approximately 3-5%, which appears to be lower than the risk of twins with clomiphene citrate (7-8%), but is still higher than the risk of twins in a spontaneous pregnancy (2-3%).
    [Show full text]
  • A Randomized Phase II Study of Letrozole Versus Observation in Patients with Newly Diagnosed Uterine Leiomyosarcoma 2006-0453
    2006-0453 Revised 4/29/2009 Page 1 Protocol Page A Randomized Phase II Study of Letrozole Versus Observation in Patients with Newly Diagnosed Uterine Leiomyosarcoma 2006-0453 Core Protocol Information Short Title Letrozole versus observation in patients with newly diagnosed uterine leiomyosarcoma Study Chair: Robert Coleman Additional Contact: Aileen Maloney Jacalyn B. Gano PDOL OPR DMC Addl Cont Department: Gynecologic Oncology Phone: 713-794-1422 Unit: 1352 Full Title: A Randomized Phase II Study of Letrozole Versus Observation in Patients with Newly Diagnosed Uterine Leiomyosarcoma Protocol Type: Standard Protocol Protocol Phase: Phase II Version Status: Terminated 07/24/2017 Version: 08 Submitted by: Aileen Maloney--6/8/2009 10:18:41 AM OPR Action: Accepted by: Leola M. Jones -- 6/16/2009 1:06:28 PM Which Committee will review this protocol? The Clinical Research Committee - (CRC) 2006-0453 Revised 4/29/2009 Page 2 Protocol Body 1.0 Objectives To prolong the time to recurrence for patients with clinical stage I and II uterine LMS assigned to letrozole therapy. The primary endpoint of this study will be a prolongation of time to disease recurrence. 2.0 Background Letrozole (4,4'-(1H-1,2,4-Triazol-1-ylmethylene)bis-benzonitrile) is a synthetic achiral benzydryltriazole derivative. It is an orally active highly selective non-steroidal competitive inhibitor of the aromatase enzyme system [1,2]. Aromatase inhibitors block the aromatase enzyme, consequently lowering estrogen levels and thereby deprive the tumor of its growth stimulus. Letrozole effectively inhibits the conversion of androgens to estrogens in both in vitro and in vivo [1].
    [Show full text]
  • Cancer Drug Costs for a Month of Treatment at Initial Food and Drug
    Cancer drug costs for a month of treatment at initial Food and Drug Administration approval Year of FDA Monthly Cost Monthly cost Generic name Brand name(s) approval (actual $'s) (2014 $'s) vinblastine Velban 1965 $78 $586 thioguanine, 6-TG Thioguanine Tabloid 1966 $17 $124 hydroxyurea Hydrea 1967 $14 $99 cytarabine Cytosar-U, Tarabine PFS 1969 $13 $84 procarbazine Matulane 1969 $2 $13 testolactone Teslac 1969 $179 $1,158 mitotane Lysodren 1970 $134 $816 plicamycin Mithracin 1970 $50 $305 mitomycin C Mutamycin 1974 $5 $23 dacarbazine DTIC-Dome 1975 $29 $128 lomustine CeeNU 1976 $10 $42 carmustine BiCNU, BCNU 1977 $33 $129 tamoxifen citrate Nolvadex 1977 $44 $170 cisplatin Platinol 1978 $125 $454 estramustine Emcyt 1981 $420 $1,094 streptozocin Zanosar 1982 $61 $150 etoposide, VP-16 Vepesid 1983 $181 $430 interferon alfa 2a Roferon A 1986 $742 $1,603 daunorubicin, daunomycin Cerubidine 1987 $533 $1,111 doxorubicin Adriamycin 1987 $521 $1,086 mitoxantrone Novantrone 1987 $477 $994 ifosfamide IFEX 1988 $1,667 $3,336 flutamide Eulexin 1989 $213 $406 altretamine Hexalen 1990 $341 $618 idarubicin Idamycin 1990 $227 $411 levamisole Ergamisol 1990 $105 $191 carboplatin Paraplatin 1991 $860 $1,495 fludarabine phosphate Fludara 1991 $662 $1,151 pamidronate Aredia 1991 $507 $881 pentostatin Nipent 1991 $1,767 $3,071 aldesleukin Proleukin 1992 $13,503 $22,784 melphalan Alkeran 1992 $35 $59 cladribine Leustatin, 2-CdA 1993 $764 $1,252 asparaginase Elspar 1994 $694 $1,109 paclitaxel Taxol 1994 $2,614 $4,176 pegaspargase Oncaspar 1994 $3,006 $4,802
    [Show full text]
  • FEMARA (Letrozole) 1
    1 AUSTRALIAN PRODUCT INFORMATION - FEMARA (letrozole) 1. NAME OF THE MEDICINE letrozole 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Femara is available as coated tablets containing 2.5 mg letrozole. Excipients of known effect: lactose, galactose, milk, sulfites, sugars, ethanol. For the full list of excipients, section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Tablet containing 2.5mg letrozole; round, film coated, dark yellow, marked FV on one side and CG on the other; in blister packs of 10 and 30 tablets. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the treatment of postmenopausal women with hormone receptor positive breast cancer (see section 5.1 Pharmacodynamic Properties, Clinical Trials). The safety and efficacy of neoadjuvant use of letrozole has not been established. Letrozole is not indicated in hormone receptor negative disease. 4.2 DOSE AND METHOD OF ADMINISTRATION Adults The recommended dose of Femara is one 2.5 mg tablet daily. In the adjuvant setting, treatment should continue for 5 years or until tumour relapse occurs, whichever comes first. In the extended adjuvant setting, the optimal treatment duration with Femara is not known. The planned duration of treatment in the pivotal study was 5 years. However, at the time of the analysis, the median duration of treatment was 24 months, 25% of patients were treated for at least three years and less than 1% of patients were treated for the planned 5 years. The median duration of follow up was 28 months. Treatment should be discontinued at tumour relapse. In the adjuvant setting the median duration of treatment was 25 months, 73% of the patients were treated for more than 2 years, 22% of the patients for more than 4 years.
    [Show full text]
  • Fertility Work up Check List
    Wilmington Health OB/GYN 1802 So 17th Street, Wilmington, NC 28401 Phone: 910-343-1031 Fax: 910-251-8896 Fertility Work up Check List Day #2-3 Labs Please call with first day of your menses. If day 2 or 3 falls on the weekend , it is ok to have blood work done on Monday. ___ FSH, LH, AMH, Prolactin, TSH, Estradiol Day # 21 lab ___ Progesterone level ( this can also be scheduled when you call with the first day of your menses and are scheduling your blood work as above). Confirms ovulation. *There may be other labs that your doctor adds to this list Radiology ___ Pelvic ultrasound- baseline, your doctor will determine the timing. ___ Hysterosalpingogram ( HSG) - this radiologic study evaluates the endometrial cavity of the uterus and fallopian tubes, to ensure that they are not blocked. This is usually done Days # 7-11 of your cycle. Please call with first day of your menses to schedule this. This is performed at New Hanover Medical Mall. For him ___ Semen analysis - 25% of infertility is associated with Male factors. This is performed at Wilmington Reproductive Laboratories, Inc. Predicting fertile time in cycle at home (*optional test, discuss with your Doctor) ___ Ovulation predictor kits at home can help us determine if an ovulatory problem is present ( 25% of the time in infertility). Here is a list of ACCURATE and FREE menstrual cycle tracking apps • Clue • Day After • FemCal Lite • The Flow • Glow • Groove • iPeriod Period Tracker Free • It's a Girl Thing • Lily • LoveCycles Menstrual, Ovulation & Period Tracker • Menstruation & Ovulation (now known as the "Menstrual Period Tracker") • Mom and Baby to Be • MonthPal ("Touchable Period Tracker") • Period Tracker • GP Apps • Period Tracker, Free Menstrual Calendar • Pink Pad Period & Fertility Tracker Pro Wilmington Health OB/GYN 1802 So 17th Street, Wilmington, NC 28401 Phone: 910-343-1031 Fax: 910-251-8896 Femara (Letrozole) Protocol • Letrozole is commonly used for infertility treatment to induce an egg to develop and to be released in women who are not ovulating on their own.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010
    NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational Safety and Health NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational Safety and Health This document is in the public domain and may be freely copied or reprinted. DISCLAIMER Mention of any company or product does not constitute endorsement by the National Institute for Occupational Safety and Health (NIOSH). In addition, citations to Web sites external to NIOSH do not constitute NIOSH endorsement of the sponsoring organizations or their programs or products. Furthermore, NIOSH is not responsible for the content of these Web sites. ORDERING INFORMATION To receive documents or other information about occupational safety and health topics, contact NIOSH at Telephone: 1–800–CDC–INFO (1–800–232–4636) TTY:1–888–232–6348 E-mail: [email protected] or visit the NIOSH Web site at www.cdc.gov/niosh For a monthly update on news at NIOSH, subscribe to NIOSH eNews by visiting www.cdc.gov/niosh/eNews. DHHS (NIOSH) Publication Number 2010−167 September 2010 Preamble: The National Institute for Occupational Safety and Health (NIOSH) Alert: Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings was published in September 2004 (http://www.cdc.gov/niosh/docs/2004-165/). In Appendix A of the Alert, NIOSH identified a sample list of major hazardous drugs. The list was compiled from infor- mation provided by four institutions that have generated lists of hazardous drugs for their respec- tive facilities and by the Pharmaceutical Research and Manufacturers of America (PhRMA) from the American Hospital Formulary Service Drug Information (AHFS DI) monographs [ASHP/ AHFS DI 2003].
    [Show full text]
  • Letrozole Once a Week Normalizes Serum Testosterone in Obesity-Related Male Hypogonadism
    European Journal of Endocrinology (2008) 158 741–747 ISSN 0804-4643 CLINICAL STUDY Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism Sandra Loves1, Janneke Ruinemans-Koerts2 and Hans de Boer1 Departments of 1Internal Medicine and 2Clinical Chemistry, Ziekenhuis Rijnstate, Wagnerlaan 55, 6800 TA Arnhem, The Netherlands (Correspondence should be addressed to H de Boer; Email: [email protected]) Abstract Objective: Isolated hypogonadotropic hypogonadism (IHH) is frequently observed in severely obese men, probably as a result of increased estradiol (E2) production and E2-mediated negative feedback on pituitary LH secretion. Aromatase inhibitors can reverse this process. This study evaluates whether letrozole once a week can normalize serum testosterone in severely obese men and maintain its long term effect. Design: Open, uncontrolled 6-month pilot study in 12 severely obese men (body mass indexO 35.0 kg/m2) with obesity-related IHH and free testosterone levels !225 pmol/l, treated with 2.5 mg letrozole once a week for 6 months. Results: Six weeks of treatment reduced total E2 from 123G11 to 58G7 pmol/l (P!0.001, meanG S.E.M.), and increased serum LH from 4.4G0.6 to 11.1G1.5 U/l (P!0.001). Total testosterone rose from 5.9G0.5 to 19.6G1.4 nmol/l (P!0.001), and free testosterone from 163G13 to 604G 50 pmol/l (P!0.001). Total testosterone rose to within the normal range in all subjects, whereas free testosterone rose to supraphysiological levels in 7 out of 12 men. The testosterone and E2 levels were stable throughout the week and during the 6-month treatment period.
    [Show full text]